Comparative Pharmacology
Head-to-head clinical analysis: FOLVITE versus NASCOBAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLVITE versus NASCOBAL.
FOLVITE vs NASCOBAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folate is reduced to tetrahydrofolate (THF) which acts as a cofactor for single-carbon transfer reactions in nucleic acid and amino acid synthesis.
Vitamin B12 (cyanocobalamin) is a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis.
1 mg orally, intramuscularly, subcutaneously, or intravenously once daily for folic acid deficiency; for pregnant and lactating women: 0.4-0.8 mg orally once daily.
1 spray (500 mcg) intranasally once weekly.
None Documented
None Documented
Terminal elimination half-life of folic acid is approximately 0.7 hours; for the active metabolite 5-methyltetrahydrofolate, half-life is 3–4 hours in plasma (tissue stores have a much longer turnover).
Approximately 6 days (depot effect due to slow release from injection site); for intramuscular doses, terminal elimination half-life is about 6 days due to gradual absorption
Primarily excreted unchanged in urine (hepatic metabolism minimal); after oral doses, fecal excretion occurs via unabsorbed drug and biliary secretion of folate metabolites accounts for a minor route.
Primarily renal (60-80% as unchanged drug), biliary/fecal (5-10%)
Category C
Category C
Vitamin
Vitamin